In the current regulatory climate of 2026, the European Union's In Vitro Diagnostic Regulation (IVDR) has made "State of the Art" (SOTA) a mandatory benchmark for performance. For manufacturers of HLA typing kits, this means that clinical performance is no longer compared just against their own previous versions, but against the highest tier of technology available in the industry. As...